durvalumab,tremelimumab
astrazeneca
[]
#gi23 60% complete response in msi-h #gastriccancer with combination immunotherapy. poor response in t4 and no correlation with cps or pd-l1 
Medical oncologist, Hematologists and integrative medicine physician.